PASITHEA THERAPEUTICS Chartanalyse

❌

Mehr »

Ad hoc-Mitteilungen:

Dienstag, 17.06.2025 - Börsentäglich über 12.000 News

Sommerexploration startet - direkt neben Ramp Metals!

Branche

Aktienmarkt

1-Jahres-Chart

5-Tage-Chart

Chart-Typ:

Zeitraum:


Tilray Brands, Inc.: Tilray Brands' Stockholders Approve Reverse Stock Split; Company Pauses Implementation as It Evaluates Timing and Stock Price	NEW YORK and LEAMINGTON, Ontario, June 10, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company... ► Artikel lesen


Tilray Brands, Inc.: Tilray Medical bringt die bekannte kanadische Cannabismarke Good Supply nach Deutschland	NEUMÜNSTER, Deutschland, May 23, 2025 (GLOBE NEWSWIRE) -- Tilray Medical ("Tilray"), ein Geschäftsbereich von Tilray Brands, Inc. (NASDAQ: TLRY und TSX: TLRY) und ein weltweit führendes Unternehmen... ► Artikel lesen


Tilray Brands, Inc.: Tilray Medical Brings Canada's Iconic Cannabis Brand Good Supply to Germany	NEUMÜNSTER, Germany, May 22, 2025 (GLOBE NEWSWIRE) -- Tilray Medical ("Tilray"), a division of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY) and a global leader in medicinal cannabis, empowering... ► Artikel lesen


Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST-Modifier Gene Therapy Candidate for Stargardt Disease	MALVERN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that... ► Artikel lesen


Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea	Upfront fees and near-term development milestone payments totaling up to $11 millionSales milestones of $150 million or more in first 10 years of commercializationRoyalties equaling 25% of net salesOcugen... ► Artikel lesen


Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST-Modifier Gene Therapy for the Treatment of Stargardt Disease	MALVERN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that... ► Artikel lesen

Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .

Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PASITHEA THERAPEUTICS CORP finden Sie auf Wallstreet Online.

PASITHEA THERAPEUTICS CORP